Entities / Person
Mike Doustdar.
CEO of Novo Nordisk
- Reports this week
- 0
- Active events
- 0
- Connections
- 10
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Earlier this month
One to three months ago
-
Novo Nordisk CEO Mike Doustdar provided an outlook on the company's market potential.Well supported12 reports
-
The FDA has granted market exclusivity for certain drugs, while analysts are comparing Novo Nordisk's development phase to AI rollouts, amidst concerns over patent cliffs.Some support2 reports
-
Eli Lilly and Company was involved in a business event in Indianapolis where Mike Doustdar acknowledged the superiority of Lilly's pill.Some support3 reports
No events began in the chosen period. Widen it, or reset.
Around Mike Doustdar this week
News at the entities that move Mike Doustdar most-
Novo Nordisk StructuralNovo Nordisk and Astellas Pharma are noted as large-cap healthcare companies, with Novo Nordisk reporting higher revenue and earnings.Moves Mike Doustdar
-
Reuters OperationalReuters and Ipsos published new poll findings regarding presidential advertisements.Moves Mike Doustdar
-
Eli Lilly and Company Mentioned togetherEli Lilly and Merck are combining therapies in clinical trials.Moves Mike Doustdar
Connections
The 3 strongest of 10, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Novo Nordisk Structural
Mike Doustdar serves as the president and CEO of Novo Nordisk, guiding its strategic direction.
-
Reuters Operational
Reuters utilizes Mike Doustdar as a source or expert regarding market trends in its reporting.
-
Eli Lilly and Company Mentioned together
Mike Doustdar publicly acknowledged the superiority of Eli Lilly's pill.